Karen C. Daily, DO, is Associate Director of Medical Oncology Clinic and an associate professor of medicine in the Division of Hematology and Oncology at the University of Florida College of Medicine.

Dr. Daily’s undergraduate degree is from The Ohio State University and her medical degree from Lake Erie College of Osteopathic Medicine. She completed a residency at Wyckoff Heights Medical Center in internal medicine and a fellowship at UF in hematology and oncology.

Dr. Daily is a clinically-based investigator and educator with a focus on breast and gynecologic cancers. She is board-certified in internal medicine, medical oncology, and hematology. She is a member of the American Society of Clinical Oncology.

Dr. Daily founded the High Risk Program, within UF Health Breast Center, that identifies women at above-average risk of developing breast cancer and offers prevention and early detection strategies. She is also committed to resolving access to care barriers in disadvantaged populations.

Dr. Staal’s professional career spans more than 35 years and includes conducting basic and applied cancer research, caring for patients, and organizing and administering a clinical cancer program. He has an interest in the molecular mechanisms that define cancer cells and how these can be exploited therapeutically. Clinically his interests are focused on experimental therapeutics, breast cancer, and clinical management to promote research and improve patient care.

Dr. George is a clinical investigator and educator with a focus on gastrointestinal malignancies. As director of the GI Oncology Program at the University of Florida, Dr. George helps to oversee the treatment of all patients with GI malignancies. He previously served as chair of the Medical Advisory Board to the State of Florida Department of Health and the Screen for Life Colorectal Cancer Screening Program, which targets historically underserved populations. He also recently completed a 10 year term as the gubernatorial-appointed chair of the Florida Cancer Control and Research Advisory Council, which advises the legislature, Department of Health, and state surgeon general on all cancer related matters and policy. He currently serves as the Associate Director for Clinical Research at the UF Health Cancer Center. Through participation with large oncology clinical trial cooperative groups and the National Cancer Institute, Dr. George is an active clinician and clinical investigator in GI malignancies and early phase clinical trials testing new therapies for patients with advanced cancers. He is a member of the medical honor society Alpha Omega Alpha, the American Society of Clinical Oncology, and numerous cancer research groups.

Brian Ramnaraign, MD is an assistant professor of medicine in the division of hematology and oncology at the University of Florida College of Medicine.

He attended the University of Toronto for his undergraduate studies where he was awarded an Honors Bachelors of Science degree with a specialization in molecular genetics and microbiology. This was followed by attending St. George’s University for his medical training where he was awarded the degree of Doctor of Medicine and graduated cum laude.

He then completed his internal medicine residency at SUNY Downstate in Brooklyn, NY followed by a fellowship in geriatrics at the University of Pennsylvania in Philadelphia, PA. He has been at the University of Florida since 2016 where he finished his hematology and oncology fellowship and has continued on as faculty.

His expertise and research interests are in the fields of genitourinary cancers and gastrointestinal cancers. He is interested in the role of targeted therapies and immunotherapies in providing personalized treatments to individuals with advanced cancers.​

Dr. Staal’s professional career spans more than 35 years and includes conducting basic and applied cancer research, caring for patients, and organizing and administering a clinical cancer program. He has an interest in the molecular mechanisms that define cancer cells and how these can be exploited therapeutically. Clinically his interests are focused on experimental therapeutics, breast cancer, and clinical management to promote research and improve patient care.

Brian Ramnaraign, MD is an assistant professor of medicine in the division of hematology and oncology at the University of Florida College of Medicine.

He attended the University of Toronto for his undergraduate studies where he was awarded an Honors Bachelors of Science degree with a specialization in molecular genetics and microbiology. This was followed by attending St. George’s University for his medical training where he was awarded the degree of Doctor of Medicine and graduated cum laude.

He then completed his internal medicine residency at SUNY Downstate in Brooklyn, NY followed by a fellowship in geriatrics at the University of Pennsylvania in Philadelphia, PA. He has been at the University of Florida since 2016 where he finished his hematology and oncology fellowship and has continued on as faculty.

His expertise and research interests are in the fields of genitourinary cancers and gastrointestinal cancers. He is interested in the role of targeted therapies and immunotherapies in providing personalized treatments to individuals with advanced cancers.​

Jonathan Chatzkel, MD is an assistant professor of medicine in the division of hematology and oncology at the University of Florida College of Medicine. Dr. Chatzkel attended the University of Pennsylvania where he graduated magna cum laude, receiving a Bachelors of Arts degree with honors in Economics. He completed his medical degree at the Perelman School of Medicine at the University of Pennsylvania, followed by an internal medicine residency at Washington University in St. Louis, MO and a hematology and oncology fellowship at the Moffitt Cancer Center in Tampa, FL. Dr. Chatzel’s clinical interests include the care of patients with genitourinary cancers, including cancers of the kidney, bladder, prostate, and testis. He believes strongly in delivering individualized care to each of his patients. Professional affiliations include the American Society of Clinical Oncology, or ASCO.

Dr. Markham is the Interim Chief of the Division of Hematology & Oncology and a professor in the Department of Medicine. She is a clinical investigator and educator with a focus on gynecologic malignancies. She serves as the Associate Director for Medical Affairs for the UF Health Cancer Center and the Research Lead for the Gynecologic Cancers Disease Site Group at UF Health Cancer Center. She is a member of the American Society of Clinical Oncology (ASCO), the Society of Gynecologic Oncologists (SGO), and the American College of Physicians (ACP), and numerous clinical trial cooperative groups.

Karen C. Daily, DO, is Associate Director of Medical Oncology Clinic and an associate professor of medicine in the Division of Hematology and Oncology at the University of Florida College of Medicine.

Dr. Daily’s undergraduate degree is from The Ohio State University and her medical degree from Lake Erie College of Osteopathic Medicine. She completed a residency at Wyckoff Heights Medical Center in internal medicine and a fellowship at UF in hematology and oncology.

Dr. Daily is a clinically-based investigator and educator with a focus on breast and gynecologic cancers. She is board-certified in internal medicine, medical oncology, and hematology. She is a member of the American Society of Clinical Oncology.

Dr. Daily founded the High Risk Program, within UF Health Breast Center, that identifies women at above-average risk of developing breast cancer and offers prevention and early detection strategies. She is also committed to resolving access to care barriers in disadvantaged populations.

Dr. Kaye is a professor of medicine, medical director of the thoracic oncology program and director of the lung cancer center within the division of hematology and oncology. He is a clinical and basic science investigator with a focus on thoracic malignancies. Dr. Kay is an elected member of the American Society for Clinical Investigation, the Alpha Omega Alpha medical honor society, and serves as Associate Editor of the Journal of the National Cancer Institute.

Ke Ning, MD, is a clinical assistant professor of medicine at the University of Florida College of Medicine in the division of hematology and oncology.

Dr. Ning attended medical school at the Ross University School of Medicine before attending University of Florida in Jacksonville to complete both his residency in internal medicine and fellowship in medical oncology. Following his fellowship, he became the director of clinical research and a principle investigator at the Hendrick Cancer Center in Abilene, Texas. He was involved in government and industry clinical trials, collaborating with the University of Texas Southwestern Medical Center as a satellite site for enrollment.

Dr. Ning is a board certified in internal medicine and medical oncology. He has been recognized with the American College of Physician’s Resident of the Year Award and has specific interests in head and neck, thoracic and cutaneous oncology. He brings compassion and individualized cancer care, and integrates the most up-to-date modalities of therapy to improve patient outcomes and quality of life.

Dr. Jones is a Professor with the Division of Hematology & Oncology at the University of Florida. He is a board certified medical oncologist with expertise in the study and treatment of lung cancer. He completed his undergraduate and medical degrees at Washington University in St. Louis, Missouri, then completed in residency in Internal Medicine at the Baylor College of Medicine in Houston, Texas, and then his fellowship in Oncology at the University of Texas MD Anderson cancer Center, where he remained on the faculty. After two years of research at Genentech, Inc., he returned to academic medicine at the University of Texas Medical Branch, and then joined the faculty of the University of New Mexico as the Director of Thoracic Oncology as well as the Medical Director of the New Mexico Cancer Care Alliance.

Dr. Nam H. Dang is a board certified medical oncologist with expertise in the study and treatment of lymphoma and chronic lymphocytic leukemia (CLL).

Dr. Lynch received his BA from the University of Virginia and MD from Eastern VA Medical School in 1984. After internal medicine training at the University of Florida, he did his training in medical oncology at the National Cancer Institute in Bethesda MD. In 1991 he returned to the UFCOM and has served in multiple roles during this tenure including, course director in Oncology (20 years), program director for hematology/oncology (13 years), section chief of hematology/oncology at the VAMC and now serves as the Assistant Dean for Admissions. He is a nationally recognized well published expert in the diagnosis and treatment of lymphomas and has coauthored over 130 papers, book chapters and abstracts. His educational roles include teaching cancer biology, clinical oncology, clinical reasoning and humanism in medicine. He was the first faculty inductee into the Chapman Humanism Society at the UFCOM and serves on its board of directors. He has received multiple teaching awards including clinical teacher of the year 5 times, the Hippocratic award three times, is a member of the College of Medicine Society of Teaching Scholars and in 2006 was honored by the University of Florida as one of 5 Distinguished Teaching Scholars. He was co-founder with his wife of the Christian Study Center at the University of Florida and serves as its board president. He and his wife Laura, have 4 children and 3 grandchildren.

Dr. Close is a Clinical Associate Professor of Medicine.  Her primary appointment is as the Associate Dean of Graduate Medical Education and the Designated Institutional Official (DIO) for the University of Florida College of Medicine. She was previously the Program Director for the Hematology/Oncology Fellowship Program.  She is a clinician educator, with research interest in curriculum related to general oncology and interactions with patients at the end of life. She is actively nationally in education, serving on the American Society of Clinical Oncology (ASCO)’s Professional Development Committee and the In-Training Exam Writing Committees for both Internal Medicine and Oncology.  She was previously Section Chief of Oncology at the Gainesville VAMC, and was the Assistant Chief of the Medical Service from 2015-2018. She previously chaired the VHA Oncology Field Advisory (FAC) Committee, a national committee providing guidance for national VA policy. She is interested in performance improvement in oncology, and has a national role in this through the VA FAC and through her membership on ASCO’s Workforce Advisory Group Committee.

Dr. Staal’s professional career spans more than 35 years and includes conducting basic and applied cancer research, caring for patients, and organizing and administering a clinical cancer program. He has an interest in the molecular mechanisms that define cancer cells and how these can be exploited therapeutically. Clinically his interests are focused on experimental therapeutics, breast cancer, and clinical management to promote research and improve patient care.

Dr. Kaye is a professor of medicine, medical director of the thoracic oncology program and director of the lung cancer center within the division of hematology and oncology. He is a clinical and basic science investigator with a focus on thoracic malignancies. Dr. Kay is an elected member of the American Society for Clinical Investigation, the Alpha Omega Alpha medical honor society, and serves as Associate Editor of the Journal of the National Cancer Institute.

Ke Ning, MD, is a clinical assistant professor of medicine at the University of Florida College of Medicine in the division of hematology and oncology.

Dr. Ning attended medical school at the Ross University School of Medicine before attending University of Florida in Jacksonville to complete both his residency in internal medicine and fellowship in medical oncology. Following his fellowship, he became the director of clinical research and a principle investigator at the Hendrick Cancer Center in Abilene, Texas. He was involved in government and industry clinical trials, collaborating with the University of Texas Southwestern Medical Center as a satellite site for enrollment.

Dr. Ning is a board certified in internal medicine and medical oncology. He has been recognized with the American College of Physician’s Resident of the Year Award and has specific interests in head and neck, thoracic and cutaneous oncology. He brings compassion and individualized cancer care, and integrates the most up-to-date modalities of therapy to improve patient outcomes and quality of life.

Dr. Jones is a Professor with the Division of Hematology & Oncology at the University of Florida. He is a board certified medical oncologist with expertise in the study and treatment of lung cancer. He completed his undergraduate and medical degrees at Washington University in St. Louis, Missouri, then completed in residency in Internal Medicine at the Baylor College of Medicine in Houston, Texas, and then his fellowship in Oncology at the University of Texas MD Anderson cancer Center, where he remained on the faculty. After two years of research at Genentech, Inc., he returned to academic medicine at the University of Texas Medical Branch, and then joined the faculty of the University of New Mexico as the Director of Thoracic Oncology as well as the Medical Director of the New Mexico Cancer Care Alliance.